Quinapril
Alternative Names: Accupril; Accuretic; AccuzideLatest Information Update: 24 Oct 2021
At a glance
- Originator Pfizer
- Developer Mitsubishi Pharma Corporation; Nonindustrial source; Pfizer
- Class Antihypertensives; Heart failure therapies; Small molecules; Tetrahydroisoquinolines
- Mechanism of Action ACE inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Heart failure; Hypertension
- No development reported Myocardial ischaemia
Most Recent Events
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 20 Oct 2003 A study has been added to the adverse events and Heart Failure therapeutic trials sections
- 06 Jul 2000 A preclinical study has been added to the Heart Failure and Ischaemic Heart Disease pharmacodynamics sections